IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Patrick C Kearney

USPTO Granted Patents = 14

Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 181(Granted Patents)


Company Filing History:

goldMedal12 out of 173 
 
Exelixis, Inc.
 patents
silverMedal2 out of 126 
 
Tularik Limited
 patents

Years Active: 2001-2016

Loading Chart...
14 patents (USPTO):Explore Patents
1. 9346807 - Inhibitors of PI3K-delta and methods of their use and manufacture (2016-05-24),
2. 8889664 - Phosphatidylinositol 3-kinase inhibitors and methods of their use (2014-11-18),
3. 8791102 - Acetanilide sphingosine-1-phosphate receptor antagonists (2014-07-29),
4. 8440663 - 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use (2013-05-14),
5. 8324231 - Pyrimidinones as casein kinase II (CK2) modulators (2012-12-04),
6. 8242129 - 6-phenylpyrimidinones as PIM modulators (2012-08-14),
7. 8101625 - Pyrimidinones as Casein Kinase II (CK2) modulators (2012-01-24),
8. 8088767 - JAK-2 modulators and methods of use (2012-01-03),
9. 8053454 - Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 (2011-11-08),
10. 7989622 - Phosphatidylinositol 3-kinase inhibitors and methods of their use (2011-08-02),
11. 7413910 - Multi-well apparatus (2008-08-19),
12. 6852290 - Multi-well apparatus (2005-02-08),
13. 6620827 - PPAR&ggr; modulators (2003-09-16),
14. 6200995 - PPAR-&ggr; modulators (2001-03-13),

Title: The Innovations of Patrick C Kearney

Introduction

Patrick C Kearney is a notable inventor based in San Francisco, CA, with a remarkable portfolio of 14 patents. His work primarily focuses on the development of pharmaceutical compounds that target critical pathways in various malignancies. Kearney's contributions to the field of medicine have the potential to significantly impact cancer treatment and prevention.

Latest Patents

Among his latest patents, Kearney has developed inhibitors of PI3K-delta, which are directed towards compounds that can be used in the treatment of various diseases. These compounds, along with their pharmaceutically acceptable salts or solvates, are designed to provide effective therapeutic options. Another significant patent involves phosphatidylinositol 3-kinase inhibitors, which are small molecule inhibitors associated with several types of cancer, including ovarian, cervical, breast, colon, rectal cancers, and glioblastomas. The compounds from this invention are aimed at treating, preventing, and inhibiting these malignancies.

Career Highlights

Kearney has had a distinguished career, working with prominent companies in the biotechnology sector. He has been associated with Exelixis, Inc. and Tularik Limited, where he has contributed to innovative research and development efforts. His expertise in the field has allowed him to make significant advancements in cancer therapeutics.

Collaborations

Throughout his career, Kearney has collaborated with esteemed colleagues, including S David Brown and James William Leahy. These partnerships have fostered a collaborative environment that has led to groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Patrick C Kearney's innovative work in developing cancer therapeutics through his patents showcases his dedication to improving medical treatments. His contributions are vital in the ongoing fight against cancer, and his legacy as an inventor continues to inspire future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…